ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - EVP, Chief Financial Officer, General Manager of ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon. And welcome to the ADMA Biologics First Quarter 2023 Financial Results and Corporate Update Conference Call on Wednesday, May 10, 2023.

ADMA Biologics, Inc. (ADMA) Q1 2023 Earnings Call Transcript

Adma Biologics (ADMA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.

Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1 ) , Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million Adjusted EBITDA Growth Expected Over the Remainder of 2023 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J.

ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, Fla.

ADMA Biologics Announces Amendment to Credit Agreement

ADMA Biologics (NASDAQ: ADMA) has reported its Q4 and full-year 2022 financial results. These are the details.

ADMA Biologics Announces Q4 And FY 2022 Results

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director of Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Securities Elliot Wilbur - Raymond James & Associates Kristen Kluska - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to the ADMA Biologics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call on Thursday, March 23, 2023. [Operator Instructions].

ADMA Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript

Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency.

ADMA Biologics: FY22 Numbers Key Inflection Point

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ADMA Biologics Announces Proposed Public Offering of Common Stock

Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - President & CEO Brian Lenz - EVP, CFO & General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, November 9, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) Q3 2022 Earnings Call Transcript

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

Arcos Dorados Hlds

Crescent Point Energy

VAALCO Energy

Itau Unibanco Holding S.A.

Kosmos Energy

NL Industries

Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfolio.

7 A-Rated Stocks to Buy for Less Than $10

AbbVie

Geron

Prometheus Biosciences

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

News for ADMA Biologics Stock (ADMA)